logo
Plus   Neg
Share
Email

Stock Alert: American Outdoor Brands Down 38%

Shares of American Outdoor Brands Corporation (AOBC) are tanking more than 38% after the firearm maker's third-quarter earnings and revenue missed estimates. Fourth-quarter and full-year outlook also remains lower than the Street estimates.

Third-quarter net income was $5.7 million, or $0.10 per share, compared with net loss of $5.7 million, or $0.10 per share, for the comparable quarter last year. Excluding items, EPS was $0.13 compared with $0.16 last year. On average, 5 analysts polled by Thomson Reuters were expecting earnings of $0.23 per share.

Quarterly net sales edged up to $166.7 million from $162.0 million for the third quarter last year.

For the fourth quarter, the company sees revenue in the range of $205 million - $215 million and EPS of $0.33- $0.37. Analysts see earnings of $0.45 per share on revenue of $224.32 million for the quarter.

For the full year, revenue is expected in the range of $650 million - $660 million and EPS in the range of $0.58- $0.62. The consensus estimate for EPS is at $0.81 on revenue of $689.65 million.

During the last 52-weeks, AOBC has traded in the range of $5.41- $11.43 and is currently at $6.47.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT